Indications for: HYPERRAB S/D

Postexposure prophylaxis of rabies (along with rabies vaccines).

Adult Dosage:

See full labeling. Give by IM inj preferably at the time of 1st vaccine dose; may be given through 7th day after 1st vaccine dose is given. Not previously vaccinated: 20 IU/kg (0.133mL/kg) once. If feasible, up to full dose should be infiltrated in area around wound and the rest (if any) into deltoid muscle of upper arm or lateral thigh muscle.

Children Dosage:

Not established.

HYPERRAB S/D Warnings/Precautions:

Previously immunized with rabies vaccine with a confirmed adequate rabies antibody titer: not recommended. Contains human plasma; monitor for possible infection transmission. IgA-deficiency. Thrombocytopenia or other bleeding disorders. Prior history of allergic reactions to human immunoglobulins. Have epinephrine inj available. Pregnancy (Cat.C).

HYPERRAB S/D Classification:

Immune globulin.

HYPERRAB S/D Interactions:

Do not administer repeated doses after administration of rabies vaccine; may suppress immune response to the vaccine. Avoid live vaccines within 3 months (eg, measles, mumps, polio, rubella).

Adverse Reactions:

Inj site reactions, mild temp elevations; rare: angioneurotic edema, rash, nephrotic syndrome, anaphylactic shock.

Generic Drug Availability:


How Supplied:

Single-dose vial (2mL, 10mL)—1